Stefano Sammicheli

Stefano Sammicheli

Company: Ichnos Sciences

Job title: Director, Innate Cell Engagers


ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of CD38 Positive Hematologic Malignancies 3:15 pm

ISB 1442 represents a novel approach for the treatment of CD38+ tumors by cotargeting CD38 and CD47 with a 2+1 biparatopic bispecific antibody format with Fc engineering enhancing Fc effector functions ISB 1442 shows higher potency relative to daratumumab in CD38high/low tumor models as measured by multiple antibody-dependent mechanisms of action in vitro and in…Read more

day: Day One

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.